Navigation Links
Vascular surgeons ask, what's next for carotid artery stenting?
Date:1/16/2008

Philadelphia, PA, January 16, 2008 A procedure called carotid artery stenting (CAS) has emerged as a minimally invasive alternative to surgery, called carotid endarterectomy (CEA), for patients with dangerous narrowing of the arteries supplying blood to the brain. However, questions remain about the best uses of this procedureespecially whether it is an appropriate alternative to surgery for "low-risk" patients, according to a special article in the January/February issue of Annals of Vascular Surgery.

"Currently, the choice of CEA versus CAS in individual patients is based more on individual practitioner experience than on clear evidence-derived guidelines," according to the new article by Drs. Philip P. Goodney and Richard J. Powell of Dartmouth-Hitchcock Medical Center, Lebanon, N.H. "Nonetheless, the popularity of less-invasive therapy combined with marketing of new CAS systems has increased the utilization of CAS."

Drs. Goodney and Powell review and summarize the research evidence on CAS to prevent stroke in patients with narrowing (stenosis) of the carotid arteries. In the CAS procedure, an expandable mesh device called a stent is placed to increase blood flow through the area of stenosis.

Recently, several randomized controlled trialsthe strongest category of scientific evidencehave directly compared the results of CAS and CEA. It has now been fairly well established that CAS and CEA yield comparable results in "high-risk" patients.

However, debate continues as to the role of CAS in the much larger group of "low-risk" patients. Some studies suggest that CAS and CEA produce similar results, but others have found a lower rate of serious complications and death in patients undergoing surgery.

Drs. Goodney and Powell note several limitations of the research that make it difficult to compare results between trials. Studies being conducted now will help to clarify the relative performance of the two techniques in both high-risk and low-risk patients. A key question will be whether CAS or CEA is the better choice for patients considered high-risk because of medical conditions.

Other issues that will need to be worked through include refinements in the design of CAS systems and the role of detailed imaging studies in guiding treatment decisions. "Ongoing randomized trials will help determine optimal revascularization strategies in the future," the authors conclude.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
3. Pot bellies linked to early signs of cardiovascular disease
4. Air pollution linked to cardiovascular risk indices in healthy young adults
5. Environmental stress probed in cardiovascular disease, diabetes
6. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
7. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
8. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
9. GrantAdler Shipping Novel Implantable Vascular Access Port
10. Design Resource Extends Support for Orthopaedic and Cardiovascular Devices
11. LeMaitre Vascular to Start Italian Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... Boulder, CO (PRWEB) , ... April 25, 2017 ... ... Law and Liberty attempts to compare student test score performance for the 2015-16 ... one of the state’s voucher programs. Though it highlights important patterns in student ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America (BPC), ... reputable physician in their area, announces the launch of a new and proprietary customer ... are looking for reputable physicians to help them with back or neck pain and ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology: